Welcome to our dedicated page for Scopus Biopharma news (Ticker: SCPS), a resource for investors and traders seeking the latest updates and insights on Scopus Biopharma stock.
Scopus Biopharma Inc. (SCPS) is an innovative biopharmaceutical company developing cutting-edge therapies for diseases with critical unmet needs. This dedicated news hub provides investors and industry professionals with essential updates on clinical trials, strategic partnerships, and therapeutic advancements.
Access timely information about SCPS's progress in immuno-oncology treatments, antiviral therapies, and regenerative medicine development. Our curated news collection features verified updates on trial milestones, research collaborations with leading institutions, and financial developments impacting the company's trajectory.
Key updates include progress reports on cancer treatment candidates, partnership announcements with academic research centers, and analyses of the company's financial position. Bookmark this page to stay informed about SCPS's contributions to biopharmaceutical innovation and their pursuit of transformative medical solutions.
Dr. Morris C. Laster, a major shareholder of Scopus BioPharma Inc. (Nasdaq: SCPS), has issued an open letter to stockholders ahead of the Annual Meeting on December 20, 2021. He criticizes the management's financial performance and calls for the removal of current Board members, urging stockholders to vote for his nominees. Dr. Laster highlights ongoing equity dilution and misrepresentation of litigation facts, stressing the need for new independent directors to protect shareholders' interests. Stockholders as of August 16, 2021, can vote using the BLUE proxy card.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced a private placement of 3,000,000 shares of common stock and additional investment options, priced at $3.25 per share, generating gross proceeds of $9.75 million. The offering will close on or about November 22, 2021. The Series A and B additional investment options will allow investors to purchase up to 3,000,000 additional shares at an exercise price of $3.125 per share. The company is required to file a registration statement with the SEC by January 4, 2022, to cover the resale of shares. This transaction is not a public offering.
Scopus BioPharma (Nasdaq: SCPS) announced the adjournment of its 2021 Annual Meeting of Stockholders to December 20, 2021, with no business conducted. This decision comes amid ongoing litigation between Scopus and Morris C. Laster, M.D. Actions have been taken to transfer 3,500,000 shares in dispute to Dr. Laster, who has been granted an irrevocable proxy for these shares. Scopus continues to solicit votes from stockholders regarding proposals set forth in its proxy statement dated September 16, 2021, as amended on October 26, 2021.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced the adjournment of its 2021 Annual Meeting of Stockholders to November 5, 2021, due to a lack of quorum. The decision follows a Stipulation and Court Order from the Delaware Court of Chancery related to claims by Morris C. Laster, M.D. Dr. Laster failed to present his shares at the meeting. Scopus continues to solicit stockholder votes for proposals set in its September 16 proxy statement. Proxies already submitted will be counted unless revoked. The meeting will be accessible online.
Scopus BioPharma (Nasdaq: SCPS) will present at the LD Micro Main Event from October 12-14, 2021, discussing the launch of its subsidiary Duet Therapeutics, focused on immuno-oncology. Alan Horsager, Ph.D., will present data on Duet's bifunctional oligonucleotides, DUET-01 and DUET-02, which enhance cancer immunotherapy effectiveness. The presentation occurs on October 12 at 11:00 AM ET. Additionally, Scopus will also present at The MicroCap Rodeo’s Fall Harvest Best Ideas Conference on October 6, 2021, at 5:00 PM ET.
Scopus BioPharma Inc. (Nasdaq: SCPS) has engaged Boies Schiller Flexner LLP to investigate market manipulation amid a significant short selling attack. In recent weeks, the company's shares have faced intense downward pressure, with a short volume ratio nearing 70% and over 25% loss in market capitalization. The legal team comprising former federal prosecutors will explore potential securities violations and pursue appropriate legal actions to protect the company and its shareholders.
Scopus BioPharma (Nasdaq: SCPS) announced its participation in The MicroCap Rodeo’s Fall Harvest Best Ideas Conference, running virtually from October 5-8, 2021. The company will showcase its newly launched subsidiary, Duet Therapeutics, focusing on immuno-oncology. Alan Horsager, Ph.D., will present preclinical data on Duet's unique bifunctional oligonucleotides, DUET-01 and DUET-02, which enhance cancer immunotherapy efficacy. Attendees can view the presentation on October 6 at 5:00 PM ET, with one-on-one meetings available for investors.
Scopus BioPharma (SCPS) announced preclinical data from Duet Therapeutics at the Oligonucleotide Therapeutics Society's annual meeting. The studies benchmarked their bifunctional oligonucleotides, DUET-01 and DUET-02, against Checkpoint Inhibitors in mice models for lymphoma and metastatic prostate cancer. Results indicate that DUET-01 led to complete lymphoma regression, while DUET-02 demonstrated potent antitumor immune responses, suggesting potential advancements in cancer immunotherapy beyond current standards. Duet plans to file INDs for DUET-02 in Q4 2022, with trials expected to begin in Q1 2023.
Scopus BioPharma (Nasdaq: SCPS) announced that its subsidiary, Duet Therapeutics, will present scientific data at the 17th Annual Meeting of the Oligonucleotide Therapeutics Society, concluding on September 29, 2021. CEO Alan Horsager will present findings on immunotherapy targeting B cell lymphoma. A new video illustrating the mechanism of action for proprietary CpG-STAT3 inhibitors was also released. DUET-01, a Phase 1 trial for B-cell non-Hodgkin lymphoma, is ongoing, with plans to file INDs for DUET-02 by Q4 2022.
Scopus BioPharma Inc. (Nasdaq: SCPS) announced that its subsidiary, Duet Therapeutics, will present scientific data at the Oligonucleotide Therapeutics Society Meeting from September 28-29, 2021. CEO Alan Horsager will showcase DUET-01, targeting B-cell lymphoma immunotherapy. Additionally, Duet released a video detailing its proprietary CpG-STAT3 inhibitors. DUET-01 is currently in a Phase 1 trial, with plans to file INDs for DUET-02 by Q4 2022 for various cancers.
